RC20 | 99% White powder Hig h Quality semaglutide weight CAS NO. 898757-96-5
TDS
898757-96-5
High Purity Grade
99%
Shenzhen
Tong Peptides
10mg/vial, 10 vials/box
2027-03-13
retatrutide,TB-500,GHK-CU,peptide
-
Product Description
-
Seller Information
-
DescriptionCertificatesBasic Info
-
Product Name:
Methanone, (3,4-dimethylphenyl)[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylmethyl)phenyl]-
Other Name:Methanone,(3,4-dimethylphenyl)[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylmethyl)phenyl]-
CAS No.:898757-96-5
Molecular Formula:C23H27NO3
InChIKeys:InChIKey=YCBQLPPQIKUZLF-UHFFFAOYSA-N
Molecular Weight:365.46500
Exact Mass:365.47
DSSTox ID:DTXSID60642864
Categories:
Characteristics-
PSA:
38.77000
XLogP3:3.81120
Density:1.19g/cm3
Boiling Point:533.7ºC at 760 mmHg
Flash Point:276.6ºC
Refractive Index:1.606
Research-
Class:
GLP-1R agonist
Status:FDA-approved (Ozempic / Wegovy / Rybelsus)
Mechanism:Long-acting, selective glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. Engineered for extended half-life (~1 week) via albumin binding (fatty acid acylation at Lys26) and resistance to DPP-4 degradation (Aib substitution at position 8). Promotes insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite via central nervous system GLP-1R activation.
Activity note:Potent, selective GLP-1R agonist. Reported binding affinity Ki = 0.38 ± 0.06 nM. Semaglutide is a human GLP-1 analog with structural modifications for albumin binding (C18 fatty diacid at Lys26) and enzymatic stability (Aib8 substitution).
Source:Lau J, et al. J Med Chem. 2015;58(18):7370-7380. Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002.DOI
Clinical Development:FDA:Ozempic, Wegovy, Rybelsus (approved 2017-12-05)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
NEJM: Wilding et al. (2021) — STEP-1; NEJM: Marso et al. (2016) — SUSTAIN-6; J Med Chem: Lau et al. (2015) — Discovery of Semaglutide; FDA: Ozempic (NDA 209637)
Disclaimer:Semaglutide is approved as a prescription medicine (Ozempic, Wegovy, Rybelsus) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
retatrutide,TB-500,GHK-CU,peptide
-
Location:
1-1, Kailuo Road, Taojia Town, Jiulongpo District, Chongqing
-
Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
501-1000
-
Year of Establishment:
2023
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
